Cargando…

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents

OBJECTIVE: Hypozincemia is a decrease in the serum zinc level of patients with hepatitis C and often requires zinc supplementation to improve the hepatic function. Our previous study showed the efficacy of direct-acting antiviral agent (DAA) treatment on serum zinc levels in patients with hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirahashi, Ryosaku, Suda, Toshikuni, Tamano, Masaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990624/ https://www.ncbi.nlm.nih.gov/pubmed/33642558 http://dx.doi.org/10.2169/internalmedicine.5738-20

Ejemplares similares

Role of liver stiffness measurements in patients who develop hepatocellular carcinoma after clearance of the hepatitis C virus
por: Gyotoku, Yoshinori, et al.
Publicado: (2022)

Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearance
por: Masaoka, Rion, et al.
Publicado: (2023)

Novel multi-parametric diagnosis of non-alcoholic fatty liver disease using ultrasonography, body mass index, and Fib-4 index
por: Funada, Kei, et al.
Publicado: (2023)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Shear wave elastography in hepatitis C patients before and after antiviral therapy
por: Suda, Toshikuni, et al.
Publicado: (2017)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy
por: Llorens-Revull, Meritxell, et al.
Publicado: (2021)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
por: Graf, Christiana, et al.
Publicado: (2020)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study
por: Muñoz-Hernández, Rocío, et al.
Publicado: (2020)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals
por: Nevola, Riccardo, et al.
Publicado: (2020)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

COVID-19 pandemic and exacerbation of ulcerative colitis
por: Suda, Toshikuni, et al.
Publicado: (2021)

Symptomatic Characteristics of Hypozincemia Detected in Long COVID Patients
por: Matsuda, Yui, et al.
Publicado: (2023)

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients
por: Cheng, Chun-Han, et al.
Publicado: (2022)

The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Era of direct acting anti-viral agents for the treatment of hepatitis C
por: Ahmed, Monjur
Publicado: (2018)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
por: Ko, Soon Young, et al.
Publicado: (2018)

Clinical, hematological, and biochemical studies on hypozincemia in neonatal calves in Egypt
por: El-Maghraby, Mamdouh M., et al.
Publicado: (2021)

Hypozincemia in COVID-19 Patients Correlates With Stronger Antibody Response
por: Xu, Wenye, et al.
Publicado: (2022)

Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients
por: Liu, Yen-Chun, et al.
Publicado: (2020)

Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents
por: Chen, Yen-Chun, et al.
Publicado: (2020)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
por: El-Mahdy, Nageh Ahmed, et al.
Publicado: (2023)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan
por: Chang, Li-Jen, et al.
Publicado: (2022)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2na4a1n1js7eo5dp88julash94